Clinical research

DOI: 10.4244/EIJ-D-22-01062

Impact of mitral regurgitation aetiology on the outcomes of transcatheter aortic valve implantation

Philipp Maximilian Doldi1,2, MD, MSc; Julius Steffen1,2, MD; Lukas Stolz1, MD; Julius Fischer1, MD; Thomas J. Stocker1,2, MD; Martin Orban1,2, MD; Hans Theiss1, MD; Konstantinos Rizas1,2, MD; Sebastian Sadoni3, MD; Christian Hagl3, MD; Steffen Massberg1,2, MD; Jörg Hausleiter1,2, MD; Daniel Braun1,2, MD, MBHA; Simon Deseive1,2, MD

Abstract

Background: Concomitant moderate/severe mitral regurgitation (MR) is observed in 17-35% of patients undergoing transcatheter aortic valve implantation (TAVI) and contributes to a worse prognosis. Studies analysing outcomes in patients undergoing TAVI with different MR aetiologies, including atrial functional MR (aFMR), are lacking.

Aims: We aimed to analyse outcomes and changes in MR severity in patients with aFMR, ventricular functional (vFMR) and primary mitral regurgitation (PMR) following TAVI.

Methods: We analysed all consecutive patients with at least moderate MR undergoing TAVI between January 2013 and December 2020 at the Munich University Hospital. Characterisation of MR aetiology was performed by detailed individual echocardiographic assessment. Three-year mortality, changes in MR severity and New York Heart Association (NYHA) Functional Class at follow-up were assessed.

Results: Out of 3,474 patients undergoing TAVI, 631 patients showed MR ≥2+ (172 with aFMR, 296 with vFMR, 163 with PMR). Procedural characteristics and endpoints were comparable between groups. The rate of MR improvement was 80.2% in aFMR patients, which was significantly higher compared to both other groups (vFMR: 69.4%; p=0.03; PMR: 40.8%; p<0.001). The estimated 3-year survival rates did not...

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 19 Number 6
Aug 21, 2023
Volume 19 Number 6
View full issue


Key metrics

On the same subject

Editorial

10.4244/EIJ-E-23-00020 Aug 21, 2023
Mitral regurgitation improvement after TAVI: if well planned, two birds are killed with one stone
Zamorano Gómez J and Pardo Sanz A
free

Clinical research

10.4244/EIJ-D-22-01037 Aug 21, 2023
Clinical outcomes of transcatheter mitral valve replacement: two-year results of the CHOICE-MI Registry
Ludwig S et al

10.4244/EIJV15I10A158 Nov 15, 2019
The five Ws of transcatheter mitral valve repair: Who, What, When, Where, and Why
Stone GW and Alfieri O
free

Clinical Research

10.4244/EIJ-D-21-00708 Jun 24, 2022
Management of patients with mitral regurgitation ineligible for standard therapy undergoing TMVI screening
Ludwig S et al
free

10.4244/EIJV16I17A252 Apr 20, 2021
How to eliminate mitral regurgitation definitively: the eternal dilemma?
Modine T and Ben Ali W
free
Trending articles
159.48

State-of-the-Art

10.4244/EIJ-D-22-00725 Jan 23, 2023
Mitral valve transcatheter edge-to-edge repair
Hausleiter J et al
free
44.7

Image – Interventional flashlight

10.4244/EIJ-D-20-00325 Sep 20, 2021
A novel technique for percutaneous mitral balloon valvuloplasty
Aurigemma C et al
free
43

Clinical Research

10.4244/EIJ-D-21-01091 Aug 5, 2022
Lifetime management of patients with symptomatic severe aortic stenosis: a computed tomography simulation study
Medranda G et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved